Got Doxy- 'Flipping the Script' on STI PEP
NCT07215325
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is being done to test the effects of doxycycline on inflammation and the bacteria in the body in people with HIV and in people on HIV pre-exposure prophylaxis. This drug is approved by the Food and Drug Administration (FDA) for the treatment of bacterial infections. The study team will investigate whether the drug has additional effects on inflammation or on the bacteria that live in the body.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Sexually Transmitted Infections (STI)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Accepted
- Sponsor
- Emory University
- Last updated on ClinicalTrials.gov
- April 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 2
- Grady Health System (non-CRN) · Atlanta, GA
- Hope Clinic · Atlanta, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.